Previous close | 13.41 |
Open | 13.65 |
Bid | 10.00 x 900 |
Ask | 18.80 x 1000 |
Day's range | 13.01 - 13.85 |
52-week range | 12.52 - 38.80 |
Volume | |
Avg. volume | 522,434 |
Market cap | 640.005M |
Beta (5Y monthly) | 1.12 |
PE ratio (TTM) | 1.99 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
One thing we could say about the analysts on uniQure N.V. ( NASDAQ:QURE ) - they aren't optimistic, having just made a...
uniQure (QURE) delivered earnings and revenue surprises of -49.25% and 96.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
We discuss a few companies like uniQure (QURE), CRISPR Therapeutics (CRSP) and Alnylam Pharmaceuticals (ALNY) with solid product portfolios and deep pipelines, which make them attractive candidates for a potential takeover in 2022.